Search 

A public pharmaceutical company with over 30 years history, and mainly focuses on Respiratory, Digestive and Oncology areas.

Pharmaceutical company

Drug delivery antibody gene

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs

Luye Pharma Group Co., Ltd. is a professional pharmaceutical enterprise built on a solid foundation of research and development and focusing on the largest and fastest growing therapeutic areas - central nervous system, oncology, cardiovascular system, and metabolism . The company was founded in 1994 and listed on the main board of the Hong Kong Stock Exchange in 2014 (02186.HK). The company has state-of-the-art production facilities located in Yantai, Nanjing, Beijing and Luzhou; as well as overseas branch offices in EU, United States, Singapore and Malaysia. The company has approximately 4,000 employees, including close to 300 R&D specialists and over 1,300 sales and marketing personnel. Luye Pharma is devoted to providing customers with high-quality innovative pharmaceutical products and professional services. The company currently sells approximately 30 products and over 80% of its total revenue is attributable to patent-protected products. Luye Pharma has an extensive sales & distribution network covering over 11,000 hospitals in 30 provinces, autonomous regions and municipalities in China, as well as exporting to many overseas countries and regions. Luye Pharma currently has 8 product candidates for overseas markets: one is preparing to submit NDA application; three are undergoing clinical trials in the US and one will start clinical trials in the US. soon.

In addition, Luye has its own biosimilar business (novel antibodies, prolia, xgeva, eylea, avastin, opdivo, trulicity, consentyx, zaltrap, CAR-T); Established in 2013, Boan Biotech is a fully-integrated biopharmaceutical company, specializing in the research & development, manufacturing and commercialization of therapeutic antibodies, which are mainly focused on key therapeutic areas such as oncology, diabetes and immunological diseases.

Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities.

Healthcare investment firm with 1.3 billion AUM

Mabgen Biotech is a Hengrui Group company, focusing on the CMC part of biologics development.

Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.